Adverse events - another week, another 93 US deaths and 3,243 US adverse events reported on VAERS

From here and here, reports of global deaths following C19 mRNA injections, for the week to 4 November 2022, for US companies making C19 mRNA injections, increased by 143 and adverse events increased by 4,999 to a cumulative 31,061 deaths and 1,458,322 adverse events, since the launch of C19 mRNA injections.

Foe the US only component of VAERS, reports of deaths following C19 mRNA injections for the week to 4 November 2022 increased by 93 and adverse events increased by 3,243, taking cumulative US deaths to 15,061 and adverse US events to 894,850.

On the bright side, the “new and improved” bivalent c19 mRNA injections do not appear to have caused many deaths or injuries.

Reports of the number of weekly deaths have tailed off markedly in the last 7 months, with just a few thousand deaths reported to VAERS from around the world.

Whether this is coincident with the leap in excess mortality to around 20% in many countries around the world, because C19 mRNA Injection deaths are NOT BEING ATTRIBUTED TO C19 mRNA INJECTIONS. Maybe all the excess deaths in countries around the world are adverse events from C19 mRNA injections.

If the 20% excess death number is valid for the US, then a ball-park estimate of the number of excess deaths for 2022 will be around 20% of 2019 (pre-pandemic) deaths of 2,854,000 = around 570,000.

For context, 2020 deaths in the US (the first year of the pandemic) were 530,000.  For the first year of the rapid uptake of C19 mRNA injections, 2021, deaths were 604,000 higher than in 2019.

Deaths were 74,000 higher in the year with C19 mRNA injections were being rolled out than the year with C19 and no injections. So much for “effective”!!!

Remember the “bait and switch” from “EVERY DEATH IS C19 if positive RT-PCR test within 28 days” to “NO DEATH IS RELATED TO c19 mRNA INJECTIONS if within 14 days of an injection”. VAERS, of course, reports events whenever they occur.

Turning to the EU/EEA, I asked the EMA where to find the number of fatalities reported to EUDRA, since the good people at VaccineImpact.com had not provided an update to this table with data to 30 July 2022.

The EMA came back within a week with details of “spontaneous” events from the six manufacturers of C19 “vaccines” plus two bivalent “vaccines” for adverse events to 12 October 2022, as reported to EUDRA on 26 October 2022.

Here is a summary table of the “spontaneous” events reported.

Assuming that “spontaneous adverse event” is analogous to “spontaneous combustion” = same day adverse event, plus “bridging” the temporal nature of adverse event reporting from VAERS (scroll down the vaersanalysis.info links at the top of the article to a bar chart of deaths from day of injection) – it looks like around 10% of adverse events from C19 mRNA injections occur within one day. So, given the assumptions of “spontaneous” meaning within one day, and, just 10% of adverse reactions occur within that one day, it is likely that these numbers can be multiplied by 10.

The EMA promptly (a member of its Stakeholder and Communications Division replied within a week) politely and kindly provided these instructions for accessing data on fatalities on EUDRA.

“The official source of information for the public on adverse reactions in the EU is the European Database of suspected Adverse Reactions (http://www.adrreports.eu), which shows reports that are sent to EudraVigilance, the EU database used for monitoring and analysing suspected side effects.

On the adrreports website, once you have selected a vaccine, you can find the number of fatalities for a selected reaction under the 6^th^ tab (Number of Individual Cases for a selected Reaction), in the Outcomes section. However, please note that the sum of the number of fatal cases per reaction will always be higher than the total number of fatal cases. This is because this website provides the number of cases reported as fatal for specific reactions groups (e.g., cardiac disorders) and for specific reactions (e.g., myocardial infarction), and one individual case often contain more than one suspected side effect.

EMA therefore publishes overall figures in the safety update reports - see section How safety is monitored on page 8 at the following link: https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccines-safety-update-10-november-2022_en.pdf “.

I haven’t attempted the navigation to each “vaccine” yet, but the response was impressive. It’s one for the “data wonks” out there to get their teeth into. I have sent the EMA another question on treatment protocols using Midazolam, morphine and Remdesivir and first, second and third likely contributors to death with C19 present. That data may not have been collected.

By the way, I asked Professor Ionnidas for the infection rate by country that accompanied the summary infection fatality rates at the same time as I requested the information from the EMA. No reply as yet!